Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jul 10:386:e078341.
doi: 10.1136/bmj-2023-078341.

Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial

Catherine M Sackley  1   2   3 , Caroline Rick  4   5 , Marian C Brady  6 , Rebecca Woolley  5 , Christopher Burton  7 , Smitaa Patel  5 , Patricia Masterson-Algar  8 , Avril Nicoll  6 , Christina H Smith  9   10 , Sue Jowett  11 , Natalie Ives  5 , Gillian Beaton  12 , Sylvia Dickson  6 , Ryan Ottridge  5 , Leslie Sharp, Helen Nankervis  1   3 , Carl E Clarke  13   14 ; PD COMM collaborative group
Affiliations
Comparative Study

Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial

Catherine M Sackley et al. BMJ. .

Abstract

Objectives: To assess the clinical effectiveness of two speech and language therapy approaches versus no speech and language therapy for dysarthria in people with Parkinson's disease.

Design: Pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.

Setting: The speech and language therapy interventions were delivered in outpatient or home settings between 26 September 2016 and 16 March 2020.

Participants: 388 people with Parkinson's disease and dysarthria.

Interventions: Participants were randomly assigned to one of three groups (1:1:1): 130 to Lee Silverman voice treatment (LSVT LOUD), 129 to NHS speech and language therapy, and 129 to no speech and language therapy. LSVT LOUD consisted of four, face-to-face or remote, 50 min sessions each week delivered over four weeks. Home based practice activities were set for up to 5-10 mins daily on treatment days and 15 mins twice daily on non-treatment days. Dosage for the NHS speech and language therapy was determined by the local therapist in response to the participants' needs (estimated from prior research that NHS speech and language therapy participants would receive an average of one session per week over six to eight weeks). Local practices for NHS speech and language therapy were accepted, except for those within the LSVT LOUD protocol. Analyses were based on the intention to treat principle.

Main outcome measures: The primary outcome was total score at three months of self-reported voice handicap index.

Results: People who received LSVT LOUD reported lower voice handicap index scores at three months after randomisation than those who did not receive speech and language therapy (-8.0 points (99% confidence interval -13.3 to -2.6); P<0.001). No evidence suggests a difference in voice handicap index scores between NHS speech and language therapy and no speech and language therapy (1.7 points (-3.8 to 7.1); P=0.43). Patients in the LSVT LOUD group also reported lower voice handicap index scores than did those randomised to NHS speech and language therapy (-9.6 points (-14.9 to -4.4); P<0.001). 93 adverse events (predominately vocal strain) were reported in the LSVT LOUD group, 46 in the NHS speech and language therapy group, and none in the no speech and language therapy group. No serious adverse events were recorded.

Conclusions: LSVT LOUD was more effective at reducing the participant reported impact of voice problems than was no speech and language therapy and NHS speech and language therapy. NHS speech and language therapy showed no evidence of benefit compared with no speech and language therapy.

Trial registration: ISRCTN registry ISRCTN12421382.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work or describe if any; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Trial flowchart. CONSORT is based on participant completed data. Participants who were partially withdrawn remained in the trial, but only had clinical follow-up. LSVT LOUD=Lee Silverman voice treatment; SLT=speech and language therapy; VHI=voice handicap index
See this image and copyright information in PMC

Comment in

References

    1. Duffy J. In: Heights M, ed. Motor speech disorders: substrates, differential diagnosis, and management. Fourth. Elsevier, 2019.
    1. Atkinson-Clement C, Letanneux A, Baille G, et al. . Psychosocial impact of dysarthria: the patient-reported outcome as part of the clinical management. Neurodegener Dis 2019;19:12-21. 10.1159/000499627 - DOI - PubMed
    1. Heberlein IVP. The influence of speech disturbances on quality of life and coping strategies on Parkinson’s disease patients. Forum Logopadie, 2005: 26-31.
    1. Spurgeon L, Clarke CE, Sackley C. Subjective experiences of speech and language therapy in patients with parkinson’s disease: a pilot study. Rehabil Res Pract 2015;2015:839895. 10.1155/2015/839895 - DOI - PMC - PubMed
    1. Prenger MTM, Madray R, Van Hedger K, Anello M, MacDonald PA. Social Symptoms of Parkinson’s Disease. Parkinsons Dis 2020;2020:8846544. 10.1155/2020/8846544 - DOI - PMC - PubMed

Associated data